NCT04687020View on ClinicalTrials.gov

Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 10, 2021

Primary Completion Date

September 30, 2032

Study Completion Date

October 31, 2032

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Viltolarsen

Received during weekly intravenous infusions

Trial Locations (5)

23230

Children's Hospital of Richmond at VCU, Richmond

27710

Duke University Medical Center, Durham

60611

Lurie Children's Hospital, Chicago

95817

UC Davis, Sacramento

T3B 6A8

Alberta Children's Hospital, Calgary

Sponsors

Lead Sponsor

NS Pharma, Inc.
All Listed Sponsors
lead

NS Pharma, Inc.

INDUSTRY

NCT04687020 - Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502) | Biotech Hunter | Biotech Hunter